Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLCSep 11Trial updateBeiGeneSino Biopharmaceutical
BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancersSep 2Trial updateBeiGenetislelizumab
BeOne Medicines files STAR Market interim report, discloses R&D spend by product under US GAAPAug 26Quarterly updateBeiGene
FDA approves Ziihera in two regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionJazz Pharmaceuticalszanidatamab-hrii
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
BeOne Medicines registers Phase 2 tislelizumab dosing study in Japanese ESCC patientsJul 29Trial updateBeiGenetislelizumab
Summit reports Q2 2026 results as HARMONi OS data hold up in western patientsJul 23Clinical readoutGlaxoSmithKlineivonescimab
BeOne Medicines registers Phase 1 bioavailability study for PRMT5 inhibitor BGB-58067Jul 17Weekly roundup, 2 itemsalcestobartBeiGene
BeiGene's LBL-007/tislelizumab colorectal cancer trial posts resultsJun 30Trial updatealcestobartBeiGene
Sign inSign in